Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010998 | 0.92 | RARB (0.44) | RARBMAPTRAB9AL3MBTL1GPR55 | |
| SCHEMBL22010955 | 0.86 | RARB (0.40) | RARBMAPTRAB9AL3MBTL1GPR55 | |
| SCHEMBL22010835 | 0.85 | RARB (0.40) | RARBMAPTRAB9AL3MBTL1GPR55 | |
| SCHEMBL22011802 | 0.84 | CTSL (0.38) | MAPTGPR55 | |
| SCHEMBL22011122 | 0.83 | MAPT (0.32) | MAPTRAB9AL3MBTL1GPR55PPARG | |
| SCHEMBL22011002 | 0.81 | L3MBTL1 (0.38) | MAPTL3MBTL1S1PR1 | |
| SCHEMBL22011803 | 0.80 | CALM1 (0.35) | MAPTRAB9AL3MBTL1GPR55S1PR1 | |
| SCHEMBL20102438 | 0.78 | RARB (0.37) | RARBMAPTRAB9AL3MBTL1GPR3 | |
| SCHEMBL22010811 | 0.78 | KDM4E (0.36) | MAPTGPR55 | |
| SCHEMBL22010968 | 0.77 | PGAM1 (0.42) | L3MBTL1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | RARB 2226/4885MAPT 1234/4885RAB9A 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.